Aztlan Global Stock Selection DM SMID ETF
AZTD - ETF AI Analysis
Top Page
Aztlan Global Stock Selection DM SMID ETF (AZTD)
AZTD’s rating suggests it is a reasonably solid, but not top-tier, ETF, supported by several strong companies with good profitability and growth prospects. Holdings like Maplebear (CART) and Exelixis (EXEL) contribute positively through strong financial performance, strategic initiatives, and generally favorable outlooks, while names such as Lumentum (LITE) and Kyndryl (KD) add some risk due to financial and revenue challenges. The main risk factor is that several holdings show bearish or mixed technical trends and pockets of high leverage or potential overvaluation, which can increase volatility for investors.
AZTD vs. SPDR S&P 500 ETF (SPY)
- AUM
- 33.79M
- Region
- Developed Markets
- Expense Ratio
- 0.75%
- Beta
- 1.00
- Issuer
- Aztlan
- Inception Date
- Aug 17, 2022
- Dividend Yield
- 1.00%
- Asset Class
- Equity
- Index Tracked
- Solactive Aztlan Global Developed Markets SMID Cap Index - Benchmark TR Net
AZTD Summary
AZTD is an ETF that follows the Solactive Aztlan Global Developed Markets SMID Cap Index, focusing on smaller and mid-sized companies in developed countries like the U.S., Japan, and the UK. It spreads investments across many sectors, including technology, consumer companies, and healthcare. Well-known holdings include DocuSign and Halozyme. Someone might invest in AZTD to seek growth from up-and-coming companies while still staying in developed markets and to diversify beyond large, well-known stocks. A key risk is that smaller companies can be more volatile, so the ETF’s price can move up and down more sharply than broad market funds.
How much will it cost me?
This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s more actively managed and focuses on a specialized group of small- and mid-cap stocks in developed markets.
What would affect this ETF?
This ETF focuses on small and mid-sized companies in developed markets, so it could benefit if global economic growth stays solid and sectors like technology, consumer cyclical, and health care continue to innovate and gain demand, helping holdings such as DocuSign and Halozyme. On the other hand, it may face pressure if interest rates rise and make riskier growth stocks less attractive, if consumer spending weakens in developed markets, or if new regulations and market volatility hurt smaller companies more than large, established firms.
AZTD Top 10 Holdings
AZTD leans into innovative small and mid-cap names, with a clear tilt toward tech and growth stories across developed markets. Japanese specialty retailer Happinet and U.S. software players like DocuSign and Cybozu have been rising, giving the fund a helpful tailwind. Health care names Halozyme and Exelixis add steady, science-driven upside, while Lumentum’s strong rebound in optical and AI hardware has quietly become a key engine. The main drag is Kyndryl, whose lagging performance shows that not every turnaround story is paying off yet.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Clear Secure | 2.48% | $848.94K | $7.28B | 48.90% | 77Outperform | |
| CarGurus | 2.24% | $767.87K | $3.10B | -3.87% | 68Neutral | |
| PHC Holdings Corp. | 2.17% | $744.39K | JPY 178.77B | 25.51% | 68Neutral | |
| Yeti Holdings | 2.03% | $695.29K | $3.12B | -0.80% | 78Outperform | |
| Koninklijke Bam Groep NV | 2.35% | $806.25K | EUR 3.67B | 76.97% | 74Outperform | |
| Vontobel Holding AG | 2.17% | $744.86K | CHF 5.29B | 56.62% | 66Neutral | |
| DaVita | 2.03% | $694.73K | $11.54B | 40.83% | 59Neutral | |
| Enova International | 2.10% | $720.93K | $4.19B | 29.26% | 71Outperform | |
| Haemonetics | 2.06% | $707.21K | $5.49B | 67.82% | 70Outperform | |
| Coca-Cola Bottling Co Consolidated | 2.11% | $724.49K | $14.10B | 32.84% | 72Outperform |
AZTD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For AZTD, the sentiment is Negative. The current price of 30.02 is below the 20-day moving average (MA) of 30.96, below the 50-day MA of 31.00, and below the 200-day MA of 31.34, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 41.15 is Neutral, neither overbought nor oversold. The STOCH value of 43.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTD.
AZTD Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $30.02 | $34.00(13.27% Upside) | $33.79M | 0.75% | 67Neutral | |
| $63.36 | $77.67(22.60% Upside) | $42.67M | 0.75% | 69Neutral | |
| $27.74 | $35.92(29.48% Upside) | $19.60M | 0.49% | 69Neutral | |
| $38.24 | $39.95(4.46% Upside) | $15.28M | 0.80% | 61Neutral | |
| $28.32 | $31.38(10.80% Upside) | $1.13M | 0.60% | 58Neutral | |
| $27.71 | $34.47(24.37% Upside) | $1.09M | 0.65% | 74Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AZTD | Aztlan Global Stock Selection DM SMID ETF | 30.02 | 2.80 | 10.29% | |
| KNO | AXS Knowledge Leaders ETF | 63.35 | 12.94 | 25.67% | |
| TNXT | T. Rowe Price Innovation Leaders ETF | 27.74 | 2.89 | 11.63% | |
| HDMV | First Trust Horizon Managed Volatility Developed Intl ETF | 38.24 | 4.61 | 13.72% | |
| WDAI | Pacer S&P World 3AI Top 300 ETF | 28.32 | 2.70 | 10.55% | |
| GLBL | Pacer MSCI World Industry Advantage ETF | 27.71 | 3.13 | 12.72% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
